Introduction
Small bowel capsule endoscopy (SBCE) is widely used as a primary diagnostic modality for suspected small bowel Crohn’s disease. However, current evidence regarding its diagnostic yield, accuracy and safety is largely derived from studies with small sample sizes and mixed patient cohorts.
Aims & Methods
We conducted a retrospective cohort study including all consecutive adult patients who underwent SBCE for suspected Crohn's disease between January 2020 and December 2025 at one of the largest SBCE centres in Europe. Extracted data included patient demographics, clinical indications, diagnostic yield and adverse events. Diagnostic accuracy of SBCE was calculated using the final clinical diagnosis as the reference standard. Capsule retention was defined as the capsule remaining in the gastrointestinal tract for more than 14 days post-ingestion.
Results
A total of 1,411 patients (61% female; median age 42.7 years, IQR 31.3 – 56.3) underwent 1,499 SBCE procedures during the study period. Fifty-four procedures (3.6%) were non-diagnostic. The overall diagnostic yield for small bowel Crohn’s disease was 26.0% (95% CI, 23.8 – 28.3), corresponding to a number needed to test of 4. Ultimately, 20.2% (95% CI, 18.2 – 22.4) of patients received a formal diagnosis of small bowel Crohn’s disease. SBCE had a sensitivity of 85.1% (95% CI, 83.2 – 87.0), specificity of 87.7% (95% CI, 86.0 – 89.5), positive predictive value of 64.4% (95% CI, 62.0 – 67.0), and negative predictive value of 95.8% (95% CI, 94.7 – 96.8). The capsule retention rate was 0.47% (95% CI, 0.19 – 0.96).
Conclusion
In the largest real-world cohort to date, SBCE demonstrated a high diagnostic yield, robust overall accuracy and excellent safety profile in patients with suspected Crohn’s disease. These findings could serve as a benchmark for quality indicators in SBCE.